Skip to main content

Recent News Releases

Recent News Releases

COVID-19 Update
14 Sep 2020

CSL continues to provide medicines to patients around the world.

Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation
26 May 2020

“The Fight Is In Us” Campaign Seeks to Mobilize COVID-19 Survivors to Accelerate the Development of Potentially Lifesaving Therapies

CSL Behring and SAB Therapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic
08 Apr 2020

King of Prussia, Pa. and Sioux Falls, S.D., April 8, 2020

COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology,
on-track for clinical evaluation as early as summer

Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy
06 Apr 2020

Osaka, JAPAN, and King of Prussia, PA, USA

Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19

Our Offer To Help Battle Coronavirus
18 Mar 2020

To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing.

HAEGARDA® is now available in the province of Québec for the routine prevention of Hereditary Angioedema (HAE) attacks in adolescent and adult patients
05 Feb 2020

HAEGARDA is a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.

Now approved by Health Canada: Hizentra®
10 Oct 2018

Now approved by Health Canada: Hizentra® (Subcutaneous Immunoglobulin [Human] 20% Liquid) for the Treatment of Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for maintenance therapy

Lifesaving Medicines Donated For Patients In The Developing World
12 Apr 2018

Ottawa – CSL Behring has shipped more than 10 million international units (IUs) of its medicines to treat hemophilia A to the WFH Global Alliance for Progress (GAP)Program in recognition of World Hemophilia Day.

Press Release Archive

If you are interested in global news from CSL Behring, please visit our Global Press Releases.